Sandbox 645: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 72: | Line 72: | ||
4) Nelfinavir (Viracept), Nelfinavir was approved by the FDA in March, 1997. <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[Viracept]]) has not been effectively evaluated in pregnant women. Viracept prevents T-cells that have been infected with HIV from producing new HIV. Usually given to patients through tablets. Each tablet contains inactive ingredients such as: calcium silicate, magnesium stearate, hypromellose, and triacetin.<ref>PMID:11364528</ref> | 4) Nelfinavir (Viracept), Nelfinavir was approved by the FDA in March, 1997. <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[Viracept]]) has not been effectively evaluated in pregnant women. Viracept prevents T-cells that have been infected with HIV from producing new HIV. Usually given to patients through tablets. Each tablet contains inactive ingredients such as: calcium silicate, magnesium stearate, hypromellose, and triacetin.<ref>PMID:11364528</ref> | ||
[[Image:Nelfin1.gif|500px|thumb|center|Nelfinavir is slightly soluble in water at pH ≤ 4 and completely soluble in methanol.]] | [[Image:Nelfin1.gif|500px|thumb|center|Nelfinavir is slightly soluble in water at pH ≤ 4 and completely soluble in methanol.]] | ||
